Immediate Release Capsule for On-Demand Sexual Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for premature ejaculation, such as SSRIs, require chronic daily administration and can lead to long-term side effects, making them impractical and unsafe for many patients.
Innovation Solution
The development of immediate release (ID) capsules containing SSRIs like dapoxetine, allowing for on-demand administration prior to sexual activity, which provides a more effective and safer treatment option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SSRIs are administered as slow release orally ingested tablets in a chronic daily regimen, then the treatment maintains continuous therapeutic effect, but it leads to serious long-term side effects and requires constant medical follow up
Solution Approach 1:
The patent transforms the continuous chronic daily administration into periodic on-demand administration. The immediate release capsule is taken only 1-3 hours before anticipated sexual activity, creating a periodic dosing pattern that provides therapeutic effect only when needed, thereby avoiding continuous exposure and long-term side effects while maintaining reliability during the treatment window
2Speed
If SSRIs are administered as immediate release orally ingested tablets, then the drug releases rapidly, but it cannot provide controlled delivery and requires chronic daily dosing
Solution Approach 1:
The patent changes the release kinetics parameter from slow release to immediate release, and simultaneously changes the dosing frequency parameter from chronic daily to on-demand. The immediate release capsule contains the SSRI in a formulation that rapidly dissolves and releases the drug, enabling the patient to take it only 1-3 hours before sexual activity rather than daily, thus improving both speed of action and ease of operation
3Duration of action of moving object
If SSRIs are administered chronically over an indefinite timespan, then the treatment maintains therapeutic effect, but it is impractical and leads to sexual dysfunction and other serious issues
Solution Approach 1:
The patent employs preliminary action by administering the immediate release capsule 1-3 hours before anticipated sexual activity. This timing ensures the drug is absorbed and active in the system precisely when needed, providing therapeutic effect during the sexual encounter without requiring prolonged continuous treatment, thereby avoiding long-term harmful effects while maintaining adequate duration of action during the treatment window
Data Source
AI summary
In various embodiments compositions for the treatment of sexual dysfunction, particularly premature ejaculation, comprise at least one selective serotonin reuptake inhibitor (an SRRI) and a carrier encased in a rapidly disintegrating immediate release capsule shell. In preferred embodiments, the carrier comprises microcrystalline cellulose that functions as both bulk filler and disintegrant. The PE compositions herein are administered in capsule dosage form as needed rather than continuously, thus drastically reducing the risk for long term health issues seen with chronic daily SRRI regimens.